Loading
companiesCompany
SARC (Sarcoma Alliance for Research through Collaboration)
SARC is a US non-profit sarcoma research organisation founded in 2003 by sarcoma physicians at five medical centres to run collaborative trials; in OnCo it leads SARC028, the pembrolizumab study across sarcoma subtypes.
Also called: Sarcoma Alliance for Research through CollaborationSARC
Overview
SARC (Sarcoma Alliance for Research through Collaboration) is a US 501(c)(3) non-profit cancer research organisation dedicated to research for the prevention, treatment and cure of sarcoma; it was formed in 2003 by a core group of medical and paediatric sarcoma experts at five major medical facilities, received a National Cancer Institute SPORE grant in 2012, and gives its address as P.O. Box 406, Ann Arbor, Michigan (sarctrials.org). ClinicalTrials.gov names it lead sponsor (OTHER class, with Merck Sharp & Dohme as collaborator) of SARC028 (NCT02301039, phase 2, pembrolizumab in advanced soft tissue and bone sarcoma), the trial recorded in OnCo. It has no products of its own.
Headquarters
Ann Arbor, Michigan, US
Website
Founded
2003
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Sarcoma Alliance for Research through Collaboration, including child institutions. 2 works · 23 citations · 50% open access · 50% clinical trials · 0% reviews.
Oncology works per year
02022
02023
12024
02025
12026
Most works
- Brian P. Rubin1 works
- Scott H. Okuno1 works
- Dale Randall Shepard1 works
- Breelyn Ann Wilky1 works
- Caroline Astbury1 works
- Gary K. Schwartz1 works
- Michael J. Wagner1 works
- Scott M. Schuetze1 works
- Kristen N. Ganjoo1 works
- Mia C. Weiss1 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma 10.1158/1078-0432.ccr-23-3817 · open access | Clinical Cancer Research | 2024 | 23 |
| SARC046: A phase II trial of nab-sirolimus in patients with progressing or symptomatic epithelioid hemangioendothelioma. conference abstract · 10.1200/jco.2026.44.16_suppl.tps11592 | Journal of Clinical Oncology | 2026 | 0 |
Similar pages
- CompanyItalian Sarcoma Group
Shares Undifferentiated pleomorphic sarcoma (UPS), Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyFrench Sarcoma Group
Shares Ewing sarcoma, Osteosarcoma, Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyScandinavian Sarcoma Group
Shares Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyAIO (Arbeitsgemeinschaft Internistische Onkologie)
Shares Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyChildren's Cancer and Leukaemia Group
Shares Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyChildren's Oncology Group (COG)
Shares Ewing sarcoma, Osteosarcoma, Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- CompanyEORTC
Shares Sarcomas (soft tissue, bone, GIST) and the tag cooperative-group.
- Key paperSARC028: pembrolizumab in advanced soft tissue and bone sarcoma